Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Stem Cell Research

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 222 articles: HTML format

Single Articles

March 2023
1. CHENG X, Huang R, Fan W, Huang S, et al
   The tear cytokine panel is a useful biomarker for early diagnosis and severity-evaluating of ocular chronic graft-versus-host disease.
   Bone Marrow Transplant. 2023 Mar 28. doi: 10.1038/s41409-023-01952.
   PubMed    
   
   
   
2. ALTAREB M, Al-Awwami M, Alfraih F, Alhayli S, et al
   "Incidence and significance of donor-specific antibodies in haploidentical stem cell transplantation".
   Bone Marrow Transplant. 2023 Mar 23. doi: 10.1038/s41409-023-01950.
   PubMed     Abstract available
   
   
   
3. CHOOLJIAN DM, Jacobs JW, Adkins BD, Savani BN, et al
   Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population.
   Bone Marrow Transplant. 2023 Mar 15. doi: 10.1038/s41409-023-01954.
   PubMed    
   
   
   
4. EL CHEIKH J, Bidaoui G, Atoui A, Terro K, et al
   Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.
   Bone Marrow Transplant. 2023 Mar 13. doi: 10.1038/s41409-023-01947.
   PubMed     Abstract available
   
   
   
5. SACCARDI R, Putter H, Eikema DJ, Busto MP, et al
   Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE
   Bone Marrow Transplant. 2023 Mar 9. doi: 10.1038/s41409-023-01924.
   PubMed     Abstract available
   
   
   
6. EBERHARDT KA, Jung V, Knops E, Heger E, et al
   CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
   Bone Marrow Transplant. 2023 Mar 3. doi: 10.1038/s41409-023-01944.
   PubMed     Abstract available
   
   
   
7. WARTHMANN A, Holbro A, Buser A, Schefer S, et al
   BleedHD-a new electronic assessment tool for grading chronic graft-versus-host disease validated in a multicenter and multiprofessional setting.
   Bone Marrow Transplant. 2023 Mar 1. doi: 10.1038/s41409-023-01945.
   PubMed    
   
   
   February 2023
8. PINANA JL, Martino R, Vazquez L, Lopez-Corral L, et al
   SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
   Bone Marrow Transplant. 2023 Feb 28:1-14. doi: 10.1038/s41409-023-01946.
   PubMed     Abstract available
   
   
   
9. AGHEL N, Lui M, Wang V, Khalaf D, et al
   Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.
   Bone Marrow Transplant. 2023 Feb 27. doi: 10.1038/s41409-023-01928.
   PubMed     Abstract available
   
   
   
10. AVERBUCH D, de la Camara R, Tridello G, Knelange NS, et al
    Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and
    Bone Marrow Transplant. 2023 Feb 27:1-9. doi: 10.1038/s41409-023-01941.
    PubMed     Abstract available
    
    
    
11. VINCI L, Flotho C, Noellke P, Lebrecht D, et al
    Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft.
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01942.
    PubMed    
    
    
    
12. NAGLER A, Labopin M, Swoboda R, Kulagin A, et al
    Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Par
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01940.
    PubMed     Abstract available
    
    
    
13. KAWAGUCHI K, Umeda K, Miyamoto S, Yoshida N, et al
    Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders.
    Bone Marrow Transplant. 2023 Feb 16. doi: 10.1038/s41409-023-01937.
    PubMed    
    
    
    
14. CAPOFERRI G, Walti CS, Urwyler P, Ragozzino S, et al
    Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Feb 16. doi: 10.1038/s41409-023-01936.
    PubMed    
    
    
    
15. HUANG Y, Luo C, Wu G, Huang X, et al
    Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation-A systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Feb 13. doi: 10.1038/s41409-023-01932.
    PubMed     Abstract available
    
    
    
16. MASSEI MS, Capolsini I, Mastrodicasa E, Perruccio K, et al
    HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.
    Bone Marrow Transplant. 2023 Feb 11:1-8. doi: 10.1038/s41409-023-01911.
    PubMed     Abstract available
    
    
    
17. MICHEL C, Robin M, Morisset S, Blaise D, et al
    Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.
    Bone Marrow Transplant. 2023 Feb 11. doi: 10.1038/s41409-023-01931.
    PubMed     Abstract available
    
    
    
18. MICHONNEAU D, Quignot N, Jiang H, Reichenbach D, et al
    Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
    Bone Marrow Transplant. 2023 Feb 10. doi: 10.1038/s41409-023-01930.
    PubMed     Abstract available
    
    
    January 2023
19. HERGEL LLF, Kielsen K, Weischendorff S, Ifversen M, et al
    The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Jan 31. doi: 10.1038/s41409-023-01927.
    PubMed    
    
    
    
20. SUN YQ, Zhang XH, Jiang Q, Jiang H, et al
    Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jan 25. doi: 10.1038/s41409-023-01925.
    PubMed     Abstract available
    
    
    
21. WASZCZUK-GAJDA A, Gras L, de Wreede LC, Sirait T, et al
    Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01915.
    PubMed     Abstract available
    
    
    
22. KATSUYA H, Yamaguchi K, Dung TC, Sano H, et al
    Late graft failure with donor-derived GPI-deficient cells in a mixed chimera following allogeneic bone marrow transplantation for severe aplastic anemia.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01923.
    PubMed    
    
    
    
23. SROUR M, Alsuliman T, Labreuche J, Bulabois CE, et al
    Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of
    Bone Marrow Transplant. 2023 Jan 9. doi: 10.1038/s41409-022-01898.
    PubMed     Abstract available
    
    
    December 2022
24. KIMURA SI, Shimizu H, Miyazaki T, Sakurai M, et al
    Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Dec 26. doi: 10.1038/s41409-022-01901.
    PubMed    
    
    
    
25. YANG F, Shi H, Xu T, Liu R, et al
    Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01903.
    PubMed    
    
    
    
26. CODA J, Raser K, Anand SM, Ghosh M, et al
    Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01906.
    PubMed    
    
    
    
27. LIU W, Ji J, Zou D, Cao Y, et al
    Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
    Bone Marrow Transplant. 2022 Dec 17. doi: 10.1038/s41409-022-01899.
    PubMed    
    
    
    
28. SANTORO N, Mooyaart JE, Devillier R, Koc Y, et al
    Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Bone Marrow Transplant. 2022 Dec 14. doi: 10.1038/s41409-022-01855.
    PubMed    
    
    
    
29. JAMY O, Dasher J, Chen A, Salzman D, et al
    Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Dec 12. doi: 10.1038/s41409-022-01897.
    PubMed     Abstract available
    
    
    
30. LUECK C, Tzalavras A, Wohlfarth P, Meedt E, et al
    Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.
    Bone Marrow Transplant. 2022 Dec 10. doi: 10.1038/s41409-022-01875.
    PubMed     Abstract available
    
    
    
31. GARDIN A, Castelle M, Pichard S, Cano A, et al
    Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients.
    Bone Marrow Transplant. 2022 Dec 9. doi: 10.1038/s41409-022-01886.
    PubMed     Abstract available
    
    
    
32. HARA J, Matsumoto K, Maeda N, Takahara-Matsubara M, et al
    Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors.
    Bone Marrow Transplant. 2022 Dec 8. doi: 10.1038/s41409-022-01890.
    PubMed    
    
    
    
33. GOEL M, Eugster A, Schetelig J, Bonifacio E, et al
    Potential of TCR sequencing in graft-versus-host disease.
    Bone Marrow Transplant. 2022 Dec 7. doi: 10.1038/s41409-022-01885.
    PubMed     Abstract available
    
    
    
34. SUN X, Fu H, Wang C, Zhang Y, et al
    Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection.
    Bone Marrow Transplant. 2022 Dec 1. doi: 10.1038/s41409-022-01880.
    PubMed     Abstract available
    
    
    
35. LABERKO A, Sultanova E, Idarmacheva A, Skvortsova Y, et al
    Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
    Bone Marrow Transplant. 2022 Dec 1. doi: 10.1038/s41409-022-01883.
    PubMed     Abstract available
    
    
    November 2022
36. MOISEEV I, Barabanshikova M, Dotsenko A, Smirnova A, et al
    First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens.
    Bone Marrow Transplant. 2022 Nov 30. doi: 10.1038/s41409-022-01879.
    PubMed     Abstract available
    
    
    
37. ZHOU S, Ma X, Ma C, Zhu Q, et al
    Splenic irradiation combined with plasmapheresis and rituximab: a new option reducing donor-specific antibody in haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Nov 19. doi: 10.1038/s41409-022-01868.
    PubMed    
    
    
    
38. SHIMOMURA Y, Komukai S, Kitamura T, Sobue T, et al
    Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis.
    Bone Marrow Transplant. 2022 Nov 14. pii: 10.1038/s41409-022-01871.
    PubMed     Abstract available
    
    
    
39. LUO C, Wu G, Huang X, Ding Y, et al
    Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
    Bone Marrow Transplant. 2022 Nov 10. pii: 10.1038/s41409-022-01865.
    PubMed     Abstract available
    
    
    
40. SOLH MM, Farnham C, Solomon SR, Bashey A, et al
    Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD).
    Bone Marrow Transplant. 2022 Nov 9. pii: 10.1038/s41409-022-01860.
    PubMed     Abstract available
    
    
    
41. CHU M, Hu S, Shen Y, Shen D, et al
    Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation.
    Bone Marrow Transplant. 2022 Nov 5. pii: 10.1038/s41409-022-01862.
    PubMed     Abstract available
    
    
    
42. XHAARD A, Villate A, Hamane S, Michonneau D, et al
    A 10-year retrospective analysis of Toxoplasma gondii qPCR screening in allogeneic hematopoietic stem cell transplantation recipients.
    Bone Marrow Transplant. 2022 Nov 5. pii: 10.1038/s41409-022-01861.
    PubMed     Abstract available
    
    
    
43. SVEC P, Elfeky R, Galimard JE, Higham CS, et al
    Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
    Bone Marrow Transplant. 2022 Nov 4. pii: 10.1038/s41409-022-01852.
    PubMed     Abstract available
    
    
    
44. HARA J, Matsumoto K, Maeda N, Takahara-Matsubara M, et al
    High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors.
    Bone Marrow Transplant. 2022 Nov 3. pii: 10.1038/s41409-022-01820.
    PubMed     Abstract available
    
    
    October 2022
45. GOKARN A, Shenoy R, Punatar S, Mirgh S, et al
    Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants.
    Bone Marrow Transplant. 2022 Oct 30. pii: 10.1038/s41409-022-01850.
    PubMed    
    
    
    
46. ARCHER G, Berger I, Bondeelle L, de Margerie-Mellon C, et al
    Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease?
    Bone Marrow Transplant. 2022 Oct 29. pii: 10.1038/s41409-022-01859.
    PubMed     Abstract available
    
    
    
47. ELGOHARY G, Toor AA, Gergis U
    Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2022 Oct 25. pii: 10.1038/s41409-022-01849.
    PubMed     Abstract available
    
    
    
48. RANGARAJAN HG, Crowell SA, Towerman AS, Shenoy SS, et al
    Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01854.
    PubMed    
    
    
    
49. MOUHIEDDINE TH, Moshier E, Thibaud S, Puliafito B, et al
    Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01848.
    PubMed     Abstract available
    
    
    
50. GABELLI M, Stepensky P, Ottaviano G, Mullanfiroze K, et al
    Incremental donor lymphocyte infusion to treat mixed chimerism after allogeneic stem cell transplantation in children with non-malignant diseases.
    Bone Marrow Transplant. 2022 Oct 19. pii: 10.1038/s41409-022-01844.
    PubMed    
    
    
    
51. XU L, Lu Y, Chen J, Sun S, et al
    Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results
    Bone Marrow Transplant. 2022 Oct 18. pii: 10.1038/s41409-022-01838.
    PubMed    
    
    
    
52. YAO Z, Gu B, Zhang Y, Qi J, et al
    CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Oct 17. pii: 10.1038/s41409-022-01845.
    PubMed    
    
    
    
53. YOSHIDA S, Ara T, Okada K, Mori Y, et al
    The preceding hyponatremia is a useful hallmark for the diagnosis of HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Oct 15. pii: 10.1038/s41409-022-01843.
    PubMed    
    
    
    
54. BANET A, Bazarbachi A, Labopin M, Stocker N, et al
    Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Oct 12. pii: 10.1038/s41409-022-01841.
    PubMed     Abstract available
    
    
    
55. SANTORO N, Mooyaart JE, Devillier R, Koc Y, et al
    Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Bone Marrow Transplant. 2022 Oct 10. pii: 10.1038/s41409-022-01839.
    PubMed     Abstract available
    
    
    
56. ZAMA D, Masetti R, Baccelli F, Leardini D, et al
    Antibiotic prophylaxis and management of infections in pediatric hematopoietic stem cell transplantation: a survey from the Stem Cell Transplant and the Infectious Disease Working Groups of the AIEOP network.
    Bone Marrow Transplant. 2022 Oct 7. pii: 10.1038/s41409-022-01793.
    PubMed    
    
    
    
57. BACKHAUS D, Brauer D, Pointner R, Bischof L, et al
    A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01833.
    PubMed     Abstract available
    
    
    
58. LAHTINEN AK, Koski J, Ritari J, Hyvarinen K, et al
    Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01828.
    PubMed     Abstract available
    
    
    
59. FERNANDEZ-SOJO J, Horton R, Cid J, Azqueta C, et al
    Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry.
    Bone Marrow Transplant. 2022;57:1531-1538.
    PubMed     Abstract available
    
    
    September 2022
60. QIAO X, Bilinski J, Wang L, Yang T, et al
    Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease.
    Bone Marrow Transplant. 2022 Sep 27. pii: 10.1038/s41409-022-01824.
    PubMed     Abstract available
    
    
    
61. JUNG SH, Min CK, Lee JH, Mun YC, et al
    Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909).
    Bone Marrow Transplant. 2022 Sep 22. pii: 10.1038/s41409-022-01818.
    PubMed     Abstract available
    
    
    
62. BARANWAL A, Mangaonkar A, Shah MV, Litzow MR, et al
    High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2022 Sep 21. pii: 10.1038/s41409-022-01829.
    PubMed    
    
    
    
63. MULAS O, Caocci G, Efficace F, Piras E, et al
    Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Sep 16. pii: 10.1038/s41409-022-01823.
    PubMed    
    
    
    
64. PIZZOLA CJ, Cioccio J, Rakszawski KL, Nickolich M, et al
    Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01821.
    PubMed    
    
    
    
65. ATSUTA Y, Sugita J, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01822.
    PubMed     Abstract available
    
    
    
66. KUANG P, Lin T, Chen X, Yang Y, et al
    Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells.
    Bone Marrow Transplant. 2022 Sep 8. pii: 10.1038/s41409-022-01789.
    PubMed    
    
    
    
67. SPYRIDONIDIS A, Labopin M, Brissot E, Moiseev I, et al
    Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2022 Sep 7. pii: 10.1038/s41409-022-01816.
    PubMed     Abstract available
    
    
    
68. TANG B, Cai Z, Wang Z, Lin D, et al
    Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Sep 2. pii: 10.1038/s41409-022-01797.
    PubMed     Abstract available
    
    
    
69. PECI F, Dekker L, Pagliaro A, van Boxtel R, et al
    The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022;57:1357-1364.
    PubMed     Abstract available
    
    
    August 2022
70. QI HZ, Xu J, Yang QQ, Lin R, et al
    Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission.
    Bone Marrow Transplant. 2022 Aug 30. pii: 10.1038/s41409-022-01796.
    PubMed     Abstract available
    
    
    
71. FILE B, Gergis M, Gergis U
    The effect of hematopoietic stem cell transplantation on fertility and strategies for improvement.
    Bone Marrow Transplant. 2022 Aug 29. pii: 10.1038/s41409-022-01792.
    PubMed     Abstract available
    
    
    
72. ELLIOTT J, Ahlawat S, Prince HM, Kennedy G, et al
    Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides.
    Bone Marrow Transplant. 2022 Aug 26. pii: 10.1038/s41409-022-01787.
    PubMed    
    
    
    
73. SILBERT S, Cole K, Bedoya SZ, Freeman AF, et al
    Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency.
    Bone Marrow Transplant. 2022 Aug 23. pii: 10.1038/s41409-022-01778.
    PubMed    
    
    
    
74. JACOBSEN ED, Kim HT, Jeter E, Jacobson C, et al
    Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01784.
    PubMed    
    
    
    
75. NAGLER A, Tsirigotis P
    Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01785.
    PubMed    
    
    
    
76. SUGITA J, Atsuta Y, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
    Bone Marrow Transplant. 2022 Aug 20. pii: 10.1038/s41409-022-01770.
    PubMed     Abstract available
    
    
    
77. BI X, Gergis U, Wagner JL, Carabasi M, et al
    Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
    Bone Marrow Transplant. 2022 Aug 19. pii: 10.1038/s41409-022-01780.
    PubMed     Abstract available
    
    
    
78. YUAN Y, Wong P, Butler JP, Henden A, et al
    High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Aug 15. pii: 10.1038/s41409-022-01773.
    PubMed    
    
    
    
79. BARANWAL A, Byun J, Ritz E, Kadanagowd A, et al
    Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant.
    Bone Marrow Transplant. 2022 Aug 15. pii: 10.1038/s41409-022-01779.
    PubMed    
    
    
    
80. HANNA P, Strohbehn I, Moreno D, Harden D, et al
    Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 3. pii: 10.1038/s41409-022-01767.
    PubMed    
    
    
    
81. KANG KR, Kim YJ, Ahn MB, Kang HM, et al
    Shorter duration of protection and lower geometric mean titers against A/H3N2 antigen of the quadrivalent influenza vaccine in children post-allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Aug 1. pii: 10.1038/s41409-022-01768.
    PubMed    
    
    
    July 2022
82. MA J, Sun S, Hu Y, Wu M, et al
    Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.
    Bone Marrow Transplant. 2022 Jul 25. pii: 10.1038/s41409-022-01766.
    PubMed    
    
    
    
83. PRABAHRAN A, Koldej R, Chee L, Szer J, et al
    Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.
    Bone Marrow Transplant. 2022 Jul 23. pii: 10.1038/s41409-022-01761.
    PubMed     Abstract available
    
    
    
84. BUSCA A, Gabrielli G, Sidoti F, Costa C, et al
    SARS-CoV-2 infection in a stem cell transplant recipient grafted from a SARS-CoV-2-positive donor.
    Bone Marrow Transplant. 2022 Jul 16. pii: 10.1038/s41409-022-01763.
    PubMed    
    
    
    
85. ZU Y, Li Z, Gui R, Liu Y, et al
    Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre,
    Bone Marrow Transplant. 2022 Jul 15. pii: 10.1038/s41409-022-01754.
    PubMed     Abstract available
    
    
    
86. DE KLOET LC, Bense JE, van der Stoep MYEC, Louwerens M, et al
    Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases.
    Bone Marrow Transplant. 2022 Jul 15. pii: 10.1038/s41409-022-01755.
    PubMed     Abstract available
    
    
    
87. MERLI P, Massa M, Russo A, Rea F, et al
    Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient.
    Bone Marrow Transplant. 2022 Jul 14. pii: 10.1038/s41409-022-01752.
    PubMed    
    
    
    
88. MASSOUD R, Klyuchnikov E, Gagelmann N, Zabelina T, et al
    Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation.
    Bone Marrow Transplant. 2022 Jul 13. pii: 10.1038/s41409-022-01666.
    PubMed     Abstract available
    
    
    
89. JAMY O, Arora S, Meredith R, Salzman D, et al
    Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
    Bone Marrow Transplant. 2022 Jul 9. pii: 10.1038/s41409-022-01757.
    PubMed    
    
    
    
90. TSAMADOU C, Gowdavally S, Platzbecker U, Sala E, et al
    Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01751.
    PubMed     Abstract available
    
    
    
91. JACOBS JW, Adkins BD, Wheeler AP, Booth GS, et al
    Diversity, equity, and inclusion in transfusion medicine, blood donation, and blood and bone marrow transplantation: language matters.
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01758.
    PubMed    
    
    
    
92. HASHMI S, Ram R
    The great Lazar-a Graft-versus-host-disease patient!
    Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01707.
    PubMed    
    
    
    
93. RANGARAJAN HG, Crowell SA, Towerman AS, Shenoy SS, et al
    CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.
    Bone Marrow Transplant. 2022 Jul 7. pii: 10.1038/s41409-022-01749.
    PubMed    
    
    
    
94. MARCAIS A, Mahlaoui N, Neven B, Lanternier F, et al
    Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency.
    Bone Marrow Transplant. 2022 Jul 6. pii: 10.1038/s41409-022-01739.
    PubMed     Abstract available
    
    
    
95. YINGLING SK, Gonzalez RM, Dillaman M, Seago K, et al
    Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization.
    Bone Marrow Transplant. 2022;57:1194-1197.
    PubMed    
    
    
    
96. DING L, Han DM, Yan HM, Zhou JX, et al
    Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.
    Bone Marrow Transplant. 2022;57:1086-1094.
    PubMed     Abstract available
    
    
    June 2022
97. NAGLER A, Labopin M, Cornelissen JJ, Forcade E, et al
    Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Socie
    Bone Marrow Transplant. 2022 Jun 30. pii: 10.1038/s41409-022-01742.
    PubMed     Abstract available
    
    
    
98. LE BRIS Y, Costes D, Bourgade R, Guillaume T, et al
    Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies.
    Bone Marrow Transplant. 2022 Jun 28. pii: 10.1038/s41409-022-01747.
    PubMed     Abstract available
    
    
    
99. SELVARAJAN S, Tammiraju S, Lionel S, Kulkarni U, et al
    Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Jun 27. pii: 10.1038/s41409-022-01745.
    PubMed    
    
    
    
100. LEMAIRE B, Combescure C, Chalandon Y, Vuilleumier N, et al
     Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Jun 25. pii: 10.1038/s41409-022-01737.
     PubMed     Abstract available
     
     
     
101. HOLTAN SG, Yu J, Paranagama D, Tang J, et al
     Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
     Bone Marrow Transplant. 2022 Jun 23. pii: 10.1038/s41409-022-01736.
     PubMed     Abstract available
     
     
     
102. TANG L, Wu Y, Lei R, Liu J, et al
     Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes.
     Bone Marrow Transplant. 2022 Jun 22. pii: 10.1038/s41409-022-01729.
     PubMed    
     
     
     
103. PEROVIC V, Sabol I, Grce M, Inngjerdingen M, et al
     Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network.
     Bone Marrow Transplant. 2022 Jun 11. pii: 10.1038/s41409-022-01733.
     PubMed    
     
     
     
104. LAZZARI L, Balaguer-Rosello A, Montoro J, Greco R, et al
     Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
     Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01725.
     PubMed     Abstract available
     
     
     
105. SONG Y, Chen S, Roseman J, Scigliano E, et al
     Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study.
     Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01727.
     PubMed    
     
     
     
106. LIU Y, Duan Z, Li F, Zhang X, et al
     Acute kidney injury in peripheral blood haploidentical hematopoietic stem cell transplantation: should attract enough attention.
     Bone Marrow Transplant. 2022 Jun 7. pii: 10.1038/s41409-022-01731.
     PubMed    
     
     
     
107. ELHADAD S, Chadburn A, Magro C, Van Besien K, et al
     C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
     Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01723.
     PubMed    
     
     
     
108. TAMAKI M, Matsumi S, Nakasone H, Nakamura Y, et al
     Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01730.
     PubMed     Abstract available
     
     
     
109. HANNA P, Strohbehn I, Wang Q, Frigault M, et al
     Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant.
     Bone Marrow Transplant. 2022 Jun 4. pii: 10.1038/s41409-022-01720.
     PubMed    
     
     
     
110. RUESCH M, Amar El Dusouqui S, Buhrfeind E, Buser A, et al
     Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors - first 10 years of prospective donor follow-up of Swiss donors.
     Bone Marrow Transplant. 2022;57:918-924.
     PubMed     Abstract available
     
     
     May 2022
111. PESSOA JM, da Rosa EL, Americo AD, Motta CL, et al
     Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study.
     Bone Marrow Transplant. 2022 May 30. pii: 10.1038/s41409-022-01718.
     PubMed     Abstract available
     
     
     
112. WELLS JR, Kang G, Suliman AY, Li Y, et al
     Delayed platelet recovery and mortality after allogeneic stem cell transplantation in children.
     Bone Marrow Transplant. 2022 May 28. pii: 10.1038/s41409-022-01726.
     PubMed    
     
     
     
113. NISHIDA M, Sugita J, Iwai T, Sato M, et al
     Ultrasonographic scoring system of late-onset sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01717.
     PubMed    
     
     
     
114. FERNANDEZ-SOJO J, Cid J, Azqueta C, Valdivia E, et al
     Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
     Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01722.
     PubMed    
     
     
     
115. ANDERSSON BS, Thall PF, Ma J, Valdez BC, et al
     A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan +/- clofarabine in allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2022 May 24. pii: 10.1038/s41409-022-01705.
     PubMed     Abstract available
     
     
     
116. LINGBLOM C, Andersson K, Johansson JE, Wenneras C, et al
     Multivariate modeling of eosinophil markers and other cellular immune parameters associated with the development of chronic graft-versus-host disease.
     Bone Marrow Transplant. 2022 May 23. pii: 10.1038/s41409-022-01708.
     PubMed    
     
     
     
117. ANGELOV D, Dillon J, Mellerick L, Pender E, et al
     Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease.
     Bone Marrow Transplant. 2022 May 20. pii: 10.1038/s41409-022-01713.
     PubMed    
     
     
     
118. AMONOO HL, Harnedy LE, Deary EC, Traeger L, et al
     Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study.
     Bone Marrow Transplant. 2022 May 19. pii: 10.1038/s41409-022-01711.
     PubMed     Abstract available
     
     
     
119. ALEXANDER T, Greco R
     Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).
     Bone Marrow Transplant. 2022 May 16. pii: 10.1038/s41409-022-01702.
     PubMed     Abstract available
     
     
     
120. KUSKONMAZ B, Ayvaz D, Okur FV, Aydin B, et al
     First allogeneic hematopoietic stem cell transplantation in RASGRP1 deficiency: long-term follow-up.
     Bone Marrow Transplant. 2022 May 14. pii: 10.1038/s41409-022-01704.
     PubMed    
     
     
     
121. DANYLESKO I, Peczynski C, Labopin M, Polge E, et al
     Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
     Bone Marrow Transplant. 2022 May 13. pii: 10.1038/s41409-022-01695.
     PubMed     Abstract available
     
     
     
122. FRIETSCH JJ, Miethke J, Linke P, Crodel CC, et al
     Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
     Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01701.
     PubMed     Abstract available
     
     
     
123. PENGLASE R, Englert H, Tymms K, Carr A, et al
     Successful lymphoablative autologous haematopoietic stem cell transplantation in three cases of severe autoimmune disease despite reduced dose cyclophosphamide conditioning-do we need 200 mg/kg cyclophosphamide?
     Bone Marrow Transplant. 2022 May 6. pii: 10.1038/s41409-022-01696.
     PubMed    
     
     
     
124. WIECZOREK M, Mariotto S, Ferrari S, Mosna F, et al
     Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series.
     Bone Marrow Transplant. 2022 May 5. pii: 10.1038/s41409-022-01690.
     PubMed     Abstract available
     
     
     
125. OHASHI T, Aoki J, Ando T, Ishiyama Y, et al
     Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
     Bone Marrow Transplant. 2022 May 3. pii: 10.1038/s41409-022-01678.
     PubMed     Abstract available
     
     
     
126. WADA F, Kondo T, Yamamoto R, Yamagiwa T, et al
     Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation.
     Bone Marrow Transplant. 2022 May 2. pii: 10.1038/s41409-022-01692.
     PubMed    
     
     
     April 2022
127. AL SALEH AS, Alghamdi AI, Alzahrani M, Alahmari B, et al
     Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis.
     Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01694.
     PubMed    
     
     
     
128. LIANG H, Pan L, Xie Y, Fan J, et al
     Health-related quality of life in pediatric patients with beta-thalassemia major after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Apr 29. pii: 10.1038/s41409-022-01663.
     PubMed     Abstract available
     
     
     
129. NAWAS MT, Lee JO, Flynn J, Maloy M, et al
     CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.
     Bone Marrow Transplant. 2022 Apr 28. pii: 10.1038/s41409-022-01684.
     PubMed     Abstract available
     
     
     
130. SOLA M, Bhatt V, Palazzo M, Cavalier KE, et al
     Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.
     Bone Marrow Transplant. 2022 Apr 27. pii: 10.1038/s41409-022-01689.
     PubMed     Abstract available
     
     
     
131. ZHANG R, Lu X, Tang LV, Wang HF, et al
     Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Apr 22. pii: 10.1038/s41409-022-01645.
     PubMed     Abstract available
     
     
     
132. NIEDERWIESER C, Weber B, Reichard M, Gagelmann N, et al
     Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19.
     Bone Marrow Transplant. 2022 Apr 20. pii: 10.1038/s41409-022-01660.
     PubMed    
     
     
     
133. DELIA M, Carluccio P, Gagliardi VP, Mestice A, et al
     Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.
     Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01676.
     PubMed    
     
     
     
134. SALHOTRA A, Talley M, Wu X, Tsai W, et al
     Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease.
     Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01671.
     PubMed    
     
     
     
135. SCHROEDER MA, Hari PN, Blithe A, Paranagama D, et al
     Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
     Bone Marrow Transplant. 2022 Apr 18. pii: 10.1038/s41409-022-01673.
     PubMed     Abstract available
     
     
     
136. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
     Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
     Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
     PubMed     Abstract available
     
     
     
137. LAZANA I, Floro L, Christmas T, Shah S, et al
     Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option.
     Bone Marrow Transplant. 2022 Apr 12. pii: 10.1038/s41409-022-01657.
     PubMed     Abstract available
     
     
     
138. MASOOD A, Wahab A, Iqbal Q, Davis J, et al
     Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.
     Bone Marrow Transplant. 2022 Apr 11. pii: 10.1038/s41409-022-01668.
     PubMed     Abstract available
     
     
     
139. SHIPTON MJ, Kinsella PM, Davis T, Azzato F, et al
     Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant.
     Bone Marrow Transplant. 2022 Apr 11. pii: 10.1038/s41409-022-01669.
     PubMed    
     
     
     
140. JORIS MM, Schmidt AH, Bernas SN, Feinberg J, et al
     Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association.
     Bone Marrow Transplant. 2022 Apr 9. pii: 10.1038/s41409-022-01667.
     PubMed    
     
     
     
141. PIEVANI A, Granata V, Desantis G, Antolini L, et al
     CD14 positive cells accelerate hematopoietic stem cell engraftment.
     Bone Marrow Transplant. 2022 Apr 8. pii: 10.1038/s41409-022-01662.
     PubMed     Abstract available
     
     
     
142. LIU H, Liu W, Li R, Jiao Y, et al
     A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
     Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01655.
     PubMed    
     
     
     
143. COOK J, Gonsalves WI, Gertz MA, Visram A, et al
     Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.
     Bone Marrow Transplant. 2022 Apr 2. pii: 10.1038/s41409-022-01659.
     PubMed    
     
     
     
144. MCCANN SR
     Choices: peripheral blood or marrow: natural or cloned yeasts.
     Bone Marrow Transplant. 2022;57:524-525.
     PubMed    
     
     
     March 2022
145. JANSSEN MJM, Bruns AHW, Verduyn Lunel FM, Raijmakers RAP, et al
     Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients.
     Bone Marrow Transplant. 2022 Mar 31. pii: 10.1038/s41409-022-01651.
     PubMed    
     
     
     
146. SCHNEIDEWIND L, Neumann T, Peters N, Kranz J, et al
     Significance of men's health in long-term survivors of allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2022 Mar 25. pii: 10.1038/s41409-022-01638.
     PubMed    
     
     
     
147. MACHOWICZ R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, et al
     Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
     Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01634.
     PubMed     Abstract available
     
     
     
148. JIANG JL, Chen M, Wang LN, Wan M, et al
     Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study.
     Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01643.
     PubMed    
     
     
     
149. ANDRE I, Simons L, Ma K, Moirangthem RD, et al
     Correction to: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy.
     Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01629.
     PubMed    
     
     
     
150. KARAM D, Gertz M, Lacy M, Dispenzieri A, et al
     Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant.
     Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01631.
     PubMed     Abstract available
     
     
     
151. UENO T, Ohta T, Sugio Y, Ohno Y, et al
     Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Mar 10. pii: 10.1038/s41409-022-01633.
     PubMed    
     
     
     
152. GALLI E, Sora F, Hohaus S, Bellesi S, et al
     Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
     Bone Marrow Transplant. 2022 Mar 8. pii: 10.1038/s41409-022-01632.
     PubMed    
     
     
     
153. PAHNKE S, Nygell UA, Johansson JE, Kisch A, et al
     Cancer incidence in healthy Swedish peripheral blood stem cell donors.
     Bone Marrow Transplant. 2022 Mar 7. pii: 10.1038/s41409-022-01617.
     PubMed     Abstract available
     
     
     
154. EL JURDI N, Okoev G, DeFor TE, Holtan SG, et al
     Predictors and outcomes of flares in chronic graft-versus-host disease.
     Bone Marrow Transplant. 2022 Mar 5. pii: 10.1038/s41409-022-01628.
     PubMed     Abstract available
     
     
     February 2022
155. ZHANG Z, Hasegawa Y, Hashimoto D, Senjo H, et al
     Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Feb 28. pii: 10.1038/s41409-022-01619.
     PubMed     Abstract available
     
     
     
156. FORCADE E, Chevret S, Finke J, Ehninger G, et al
     Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.
     Bone Marrow Transplant. 2022 Feb 26. pii: 10.1038/s41409-022-01620.
     PubMed     Abstract available
     
     
     
157. YESILIPEK MA, Uygun V, Kupesiz A, Karasu G, et al
     Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.
     Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01613.
     PubMed     Abstract available
     
     
     
158. LINDAHL H, Vonlanthen S, Valentini D, Bjorklund AT, et al
     Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
     Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01615.
     PubMed     Abstract available
     
     
     
159. ARSLAN S, Ali H, Mei M, Marcucci G, et al
     Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.
     Bone Marrow Transplant. 2022 Feb 22. pii: 10.1038/s41409-022-01590.
     PubMed    
     
     
     
160. HUTT D, Arjona ET, Mekelenkamp H, Galimard JE, et al
     Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians.
     Bone Marrow Transplant. 2022 Feb 21. pii: 10.1038/s41409-021-01559.
     PubMed     Abstract available
     
     
     
161. MADANCHI R, Engel NW, Alsdorf W, Oing C, et al
     Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients.
     Bone Marrow Transplant. 2022 Feb 21. pii: 10.1038/s41409-022-01614.
     PubMed     Abstract available
     
     
     
162. MORENO-CASTANO AB, Palomo M, Torramade-Moix S, Martinez-Sanchez J, et al
     An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct.
     Bone Marrow Transplant. 2022 Feb 18. pii: 10.1038/s41409-022-01610.
     PubMed     Abstract available
     
     
     
163. LEIMI L, Jahnukainen K, Olkinuora H, Meri S, et al
     Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Feb 17. pii: 10.1038/s41409-022-01607.
     PubMed     Abstract available
     
     
     
164. YOON SE, Jo H, Kang ES, Cho D, et al
     Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
     Bone Marrow Transplant. 2022 Feb 16. pii: 10.1038/s41409-022-01605.
     PubMed     Abstract available
     
     
     
165. DROZDOV D, Petermann K, Dougoud S, Oberholzer S, et al
     Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation.
     Bone Marrow Transplant. 2022 Feb 9. pii: 10.1038/s41409-022-01594.
     PubMed     Abstract available
     
     
     
166. SUH JK, Im HJ, Kang SH, Kim H, et al
     Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases.
     Bone Marrow Transplant. 2022 Feb 7. pii: 10.1038/s41409-021-01556.
     PubMed    
     
     
     
167. PIEMONTESE S, Lazzari L, Ruggeri A, Marcatti M, et al
     Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience.
     Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01600.
     PubMed    
     
     
     
168. GEVORGIAN AG, Kozlov AV, Tolkunova PS, Kazantzev IV, et al
     Tandem autologous hematopoietic stem cell transplantation for embryonal brain tumors in infants and very young children.
     Bone Marrow Transplant. 2022 Feb 3. pii: 10.1038/s41409-022-01593.
     PubMed     Abstract available
     
     
     
169. PARSONS SK, Rodday AM, Weidner RA, Morris E, et al
     Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant.
     Bone Marrow Transplant. 2022 Feb 2. pii: 10.1038/s41409-022-01584.
     PubMed     Abstract available
     
     
     
170. LINDHOLM C, Olofsson E, Creignou M, Nilsson L, et al
     Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study.
     Bone Marrow Transplant. 2022 Feb 2. pii: 10.1038/s41409-022-01582.
     PubMed     Abstract available
     
     
     
171. FRIEND BD, Muhsen IN, Patel S, Hill LC, et al
     Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
     Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-022-01599.
     PubMed     Abstract available
     
     
     
172. NAGLER A, Labopin M, Huang XJ, Blaise D, et al
     Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
     Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-021-01537.
     PubMed     Abstract available
     
     
     January 2022
173. FILE B, Huang Y, Peedin A, Gergis U, et al
     The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies.
     Bone Marrow Transplant. 2022 Jan 26. pii: 10.1038/s41409-022-01578.
     PubMed     Abstract available
     
     
     
174. SKEENS M, Guttoo P, Stanek JR, Taylor K, et al
     An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients.
     Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-022-01587.
     PubMed     Abstract available
     
     
     
175. NI F, Yin ETS, Zhou L, Zhao H, et al
     Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
     Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-021-01554.
     PubMed    
     
     
     
176. UTSUNOMIYA A, Tokunaga M, Nakano N, Fujiwara H, et al
     Long-term follow-up of patients with ATL after autologous stem cell transplantation.
     Bone Marrow Transplant. 2022 Jan 23. pii: 10.1038/s41409-021-01412.
     PubMed    
     
     
     
177. KAWAJIRI A, Kawase T, Tanaka H, Fukuda T, et al
     Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.
     Bone Marrow Transplant. 2022 Jan 21. pii: 10.1038/s41409-021-01552.
     PubMed     Abstract available
     
     
     
178. MANNINA D, Badbaran A, Wolschke C, Klyuchnikov E, et al
     Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis.
     Bone Marrow Transplant. 2022 Jan 19. pii: 10.1038/s41409-022-01566.
     PubMed    
     
     
     
179. JEPPESEN H, Kielsen K, Siersma V, Lindegaard J, et al
     Ocular graft-versus-host disease and dry eye disease after paediatric haematopoietic stem cell transplantation - incidence and risk factors.
     Bone Marrow Transplant. 2022 Jan 18. pii: 10.1038/s41409-022-01564.
     PubMed     Abstract available
     
     
     
180. HASHMI H, Shockley A, Davis JA
     'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy.
     Bone Marrow Transplant. 2022 Jan 17. pii: 10.1038/s41409-022-01570.
     PubMed    
     
     
     
181. SHAO DF, Li JH, Hu T, Zhang ZX, et al
     Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring.
     Bone Marrow Transplant. 2022 Jan 17. pii: 10.1038/s41409-021-01545.
     PubMed     Abstract available
     
     
     
182. SHIMONI A
     Relapse of acute leukemia after a second allogeneic stem- cell transplantation; Is there any hope for cure?
     Bone Marrow Transplant. 2022 Jan 14. pii: 10.1038/s41409-021-01508.
     PubMed    
     
     
     
183. SOERENSEN JF, Aggerholm A, Rosenberg CA, Bill M, et al
     Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation.
     Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-022-01567.
     PubMed     Abstract available
     
     
     
184. SHIMONI A, Labopin M, Angelucci E, Blaise D, et al
     The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
     Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-021-01493.
     PubMed     Abstract available
     
     
     
185. TRUNK AD, Shewan SK, Lee CJ, Parker CJ, et al
     Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination.
     Bone Marrow Transplant. 2022 Jan 11. pii: 10.1038/s41409-021-01543.
     PubMed    
     
     
     
186. VINCENT L, Gras L, Ceballos P, Finke J, et al
     Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
     Bone Marrow Transplant. 2022 Jan 10. pii: 10.1038/s41409-021-01560.
     PubMed    
     
     
     
187. LOSCHI M, Roux C, Sudaka I, Ferrero-Vacher C, et al
     Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
     Bone Marrow Transplant. 2022 Jan 9. pii: 10.1038/s41409-021-01544.
     PubMed     Abstract available
     
     
     
188. EL HUSSEIN S, DiNardo CD, Takahashi K, Khoury JD, et al
     Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
     Bone Marrow Transplant. 2022 Jan 7. pii: 10.1038/s41409-021-01538.
     PubMed     Abstract available
     
     
     
189. ANDOLINA JR, Wang YC, Ji L, Freyer DR, et al
     Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
     Bone Marrow Transplant. 2022 Jan 6. pii: 10.1038/s41409-021-01558.
     PubMed     Abstract available
     
     
     
190. STUTZ L, Halter JP, Heim D, Passweg JR, et al
     Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin.
     Bone Marrow Transplant. 2022 Jan 4. pii: 10.1038/s41409-021-01546.
     PubMed     Abstract available
     
     
     
191. VELIER M, Daumas A, Simoncini S, Arcani R, et al
     Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis.
     Bone Marrow Transplant. 2022;57:17-22.
     PubMed     Abstract available
     
     
     December 2021
192. BETHGE WA, Eyrich M, Mielke S, Meisel R, et al
     Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.
     Bone Marrow Transplant. 2021 Dec 24. pii: 10.1038/s41409-021-01551.
     PubMed     Abstract available
     
     
     November 2021
193. FURTADO VF, Brauneis D, Weinberg J, Elhassan N, et al
     Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.
     Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01535.
     PubMed    
     
     
     
194. LEAL CTS, Costa LJM, Pereira J, Duarte FB, et al
     Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
     Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01531.
     PubMed    
     
     
     
195. IMAHASHI N, Terakura S, Kondo E, Kato K, et al
     Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.
     Bone Marrow Transplant. 2021 Nov 24. pii: 10.1038/s41409-021-01525.
     PubMed     Abstract available
     
     
     
196. SHUMILOV E, Shakhanova I, Flach J, Schmidt N, et al
     Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.
     Bone Marrow Transplant. 2021 Nov 13. pii: 10.1038/s41409-021-01521.
     PubMed     Abstract available
     
     
     
197. HOLIG K, Schmidt H, Hutter G, Kramer M, et al
     Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
     Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01523.
     PubMed    
     
     
     
198. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
     Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
     Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01516.
     PubMed    
     
     
     
199. OTTH M, Yammine S, Usemann J, Latzin P, et al
     Longitudinal lung function in childhood cancer survivors after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01509.
     PubMed     Abstract available
     
     
     
200. SCHMID C, Labopin M, Schaap N, Veelken H, et al
     Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
     Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01515.
     PubMed     Abstract available
     
     
     
201. ALZAHRANI M, Damlaj M, Essa M, Alahmari B, et al
     HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome.
     Bone Marrow Transplant. 2021 Nov 6. pii: 10.1038/s41409-021-01513.
     PubMed    
     
     
     
202. GARNICA M, Dalcolmo S, Gaio B, de Almeida AR, et al
     Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment.
     Bone Marrow Transplant. 2021 Nov 1. pii: 10.1038/s41409-021-01520.
     PubMed    
     
     
     
203. KASIKIS S, Baez J, Gandhi I, Grupp S, et al
     Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.
     Bone Marrow Transplant. 2021;56:2869-2870.
     PubMed    
     
     
     October 2021
204. MARTINO R, Garcia-Cadenas I, Esquirol A
     Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.
     Bone Marrow Transplant. 2021 Oct 28. pii: 10.1038/s41409-021-01507.
     PubMed    
     
     
     
205. MIKULSKA M, Penack O, Wendel L, Knelange N, et al
     HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party.
     Bone Marrow Transplant. 2021 Oct 23. pii: 10.1038/s41409-021-01497.
     PubMed     Abstract available
     
     
     
206. MARTINO M, Pitino A, Gori M, Viens P, et al
     Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study.
     Bone Marrow Transplant. 2021 Oct 23. pii: 10.1038/s41409-021-01503.
     PubMed    
     
     
     
207. TIEN FM, Tsai CH, Huang SC, Liu JH, et al
     Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
     Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01454.
     PubMed     Abstract available
     
     
     
208. WANG X, Yu U, Yang C, Wang C, et al
     Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01499.
     PubMed    
     
     
     
209. SMITH PJ, Lew M, Lowder Y, Romero K, et al
     Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 Oct 19. pii: 10.1038/s41409-021-01470.
     PubMed     Abstract available
     
     
     
210. VO P, Onstad L, Flowers ME, Storb R, et al
     Cancers after HLA-matched related bone marrow transplantation for aplastic anemia.
     Bone Marrow Transplant. 2021 Oct 16. pii: 10.1038/s41409-021-01498.
     PubMed     Abstract available
     
     
     
211. CARTER M, Taniguchi M, Yang D, Arslan S, et al
     Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
     Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01494.
     PubMed    
     
     
     
212. SALVINI M, Maggi F, Damonte C, Mortara L, et al
     Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation.
     Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01487.
     PubMed    
     
     
     
213. KOBAYASHI S, Kanda Y, Konuma T, Inamoto Y, et al
     Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
     Bone Marrow Transplant. 2021 Oct 8. pii: 10.1038/s41409-021-01485.
     PubMed     Abstract available
     
     
     
214. SELLNER L, Schetelig J, Koster L, Choi G, et al
     Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
     Bone Marrow Transplant. 2021 Oct 7. pii: 10.1038/s41409-021-01490.
     PubMed    
     
     
     
215. SAVOIA C, McKeough N, Hickey B, Cochrane T, et al
     Comparison of a therapeutic platelet transfusion strategy to a prophylactic platelet transfusion strategy in autologous stem cell transplant (ASCT), a single centre experience.
     Bone Marrow Transplant. 2021 Oct 6. pii: 10.1038/s41409-021-01482.
     PubMed    
     
     
     
216. MILLARD T, Sammour F, Anthias C, Easdale S, et al
     Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?
     Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01484.
     PubMed    
     
     
     
217. POIRE X, Graux C, Ory A, Herman J, et al
     Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective s
     Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01464.
     PubMed    
     
     
     
218. PERRUCCIO K, Menconi M, Galaverna F, Pagliara D, et al
     Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses.
     Bone Marrow Transplant. 2021 Oct 4. pii: 10.1038/s41409-021-01285.
     PubMed    
     
     
     
219. NAKAMURA ZM, Heiling HM, Park EM, Deal AM, et al
     Impact of patient and clinical characteristics on cognitive changes after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 Oct 2. pii: 10.1038/s41409-021-01481.
     PubMed    
     
     
     September 2021
220. MAMEZ AC, Pradier A, Giannotti F, Petitpas A, et al
     Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
     Bone Marrow Transplant. 2021 Sep 28. pii: 10.1038/s41409-021-01466.
     PubMed    
     
     
     
221. PERIC Z, Peczynski C, Polge E, Kroger N, et al
     Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT.
     Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01458.
     PubMed    
     
     
     
222. YOKOYAMA H, Hirayama M, Takahashi Y, Uchida N, et al
     Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
     Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01469.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: